FDA Drug Development Guidances: Oncology, Diabetes, Obesity Are Priorities
Executive Summary
FDA's top priorities for drug development guidances are in the areas of oncology, diabetes and obesity
You may also be interested in...
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment
FDA/NIH diabetes public meeting
FDA and National Institutes of Health will hold a joint public meeting May 13 and 14 to discuss the treatment of type 1 and type 2 diabetes mellitus. The FDA/NIH collaboration is part of Commissioner McClellan's strategic plan to develop a regulatory framework that would encourage the development of treatments in high-need areas, such as diabetes, cancer, obesity and lupus (1"The Pink Sheet" Feb. 10, 2003, p. 5)...